| 前收市價 | 120.40 |
| 開市 | 121.79 |
| 買盤 | 122.05 x 300 |
| 賣出價 | 122.18 x 200 |
| 今日波幅 | 119.43 - 122.34 |
| 52 週波幅 | 62.55 - 170.47 |
| 成交量 | |
| 平均成交量 | 3,935,358 |
| 市值 | 46.797B |
| Beta 值 (5 年，每月) | 1.66 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -15.60 |
| 業績公佈日 | 2024年5月02日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 133.81 |
ZacksModerna (MRNA) Stock Before Q2 Earnings: To Buy or Not to Buy?
Investors will likely focus on updates on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates when it reports second-quarter earnings.
ZacksBeam Therapeutics (BEAM) Soars 7.9%: Is Further Upside Left in the Stock?
Beam Therapeutics (BEAM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Barrons.comThis Biotech Risk-Taker Created Moderna. Now He’s Harnessing AI.
Noubar Afeyan’s Flagship Pioneering has hundreds of scientists working at in-house labs. They’re seeking discoveries as valuable as the mRNA vaccines of Flagship’s best-known spinoff, Moderna.
